nach oben

Angiogenesis

Erschienen in:

01.09.2008 | Review Paper

The discovery of the placental growth factor and its role in angiogenesis: a historical review

verfasst von: Domenico Ribatti

Erschienen in: Angiogenesis | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The placental growth factor (PlGF) is an angiogenic protein belonging to the vascular endothelial growth factor (VEGF) family, which was discovered in 1991 by an Italian scientist, Maria Graziella Persico. Dr Persico cloned and purified PlGF and determined its structure by crystallography resolution. Furthermore, she identified VEGF receptor-1 (VEGFR-1) as the receptor for PlGF, and in collaboration with Dr Peter Carmeliet in Leuven, she generated evidence that loss of PlGF does not affect development, reproduction, or postnatal life. PlGF is expressed primarily in the placenta and is up-regulated in several pathological conditions, although its role is still controversial. Some data in literature reported that PlGF enhances pathological angiogenesis by initiating a cross-talk between VEGFR-1 and VEGFR-2, whereas other studies did not confirm these findings. Regarding the potential therapeutic employment of PlGF, recent evidence has shown that an anti-PlGF antibody may act as a potent antiangiogenic agent, and that it has the advantage of minor toxicity when combined with anti-VEGF strategies.

Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MB (1991) Isolation of human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 88:9267–9271. doi:10.1073/pnas.88.20.9267 PubMedCrossRef

Iyer S, Leonidas DD, Swaminathan GJ, Maglione D, Battisti M, Tucci M et al (2001) The crystal structure of human placental growth factor-1 (PlGF), an angiogenic protein at 2 Å resolution. J Biol Chem 276:12153–12161. doi:10.1074/jbc.M008055200 PubMedCrossRef

Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K et al (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8:925–931PubMed

Cao Y, Ji WR, Qi P, Rosin A, Cao Y (1997) Placenta growth factor: identification and characterization of a novel isoform generated by mRNA alternative splicing. Biochem Biophys Res Commun 235:493–498. doi:10.1006/bbrc.1997.6813 PubMedCrossRef

Yang W, Ahm H, Hinrichs M, Torry RJ, Torry DS (2003) Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human throphoblast and endothelial cells. J Reprod Immunol 60:53–60. doi:10.1016/S0165-0378(03)00082-2 PubMedCrossRef

Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R et al (1998) Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273:22272–22278. doi:10.1074/jbc.273.35.22272 PubMedCrossRef

Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M (1999) Neuropilin-1 mediates collapsin-1/ semaphorin III inhibition of endothelial cell motility: functional competion of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146:233–242PubMed

Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ et al (1996) Localisation of placenta growth factor (PlGF) in human term placenta. Growth Factors 13:243–250. doi:10.3109/08977199609003225 PubMedCrossRef

Vuorela P, Hatva E, Lymboussaki A, Kaipanen A, Joukov V, Persico MG et al (1997) Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 56:489–494. doi:10.1095/biolreprod56.2.489 PubMedCrossRef

10.

Achen MG, Gad JM, Stacker SA, Wilks AF (1997) Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development. Growth Factors 15:69–80PubMedCrossRef

11.

Persico MG, Vincenti V, Di Palma T (1999) Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 237:31–40PubMed

12.

Voros G, Maquoi E, Demeuelemeester D, Clerx N, Collen D, Lijnen HR (2005) Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 146:4545–4554. doi:10.1210/en.2005-0532 PubMedCrossRef

13.

Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M et al (2001) Synergism between vascular endothelial growth factor and placenta growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575–583. doi:10.1038/87904 PubMedCrossRef

14.

Lijnen HR, Christiaens V, Scroyen I, Voros G, Tjwa M, Carmeliet P et al (2006) Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes 55:2698–2704. doi:10.2337/db06-0526 PubMedCrossRef

15.

Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M et al (1997) Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab Invest 76:517–531PubMed

16.

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:81–840. doi:10.1038/nm0102-81 CrossRef

17.

Autiero M, Waltenberger J, Communni D, Kranz A, Moons L, Lambrechts D et al (2003) Role of PlGF in the intra- and inter-molecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936–943. doi:10.1038/nm884 PubMedCrossRef

18.

Viita H, Markkanen J, Eriksson E, Nurminen M, Kinnunen K, Babu M et al (2008) 15-Lipoxygenase-1 prevents vascular endothelial growth factor-A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. Circ Res 102:177–184. doi:10.1161/CIRCRESAHA.107.155556 PubMedCrossRef

19.

Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L et al (2002) Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 115:2559–2567PubMed

20.

Inoue N, Kondo T, Kobayashi K, Aoki M, Numaguchi Y, Shibuya M et al (2006) Therapeutic angiogenesis using novel vascular endothelial growth factor-E/human placental growth factor chimera genes. Arterioscler Thromb Vasc Biol 27:99–105. doi:10.1161/01.ATV.0000251504.61247.d5 PubMedCrossRef

21.

Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, Yamaguchi S et al (2006) Chimeric VEGF-E_NZ7/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 26:2019–2026. doi:10.1161/01.ATV.0000233336.53574.a1 PubMedCrossRef

22.

Bottomley MJ, Webb NJ, Watson CJ, Holt L, Bukhari M, Denton J et al (2000) Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol 119:182–188. doi:10.1046/j.1365-2249.2000.01097.x PubMedCrossRef

23.

Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD et al (2003) Placenta growth factor activated monocytes and correlates with sickle disease severity. Blood 102:1506–1514. doi:10.1182/blood-2002-11-3422 PubMedCrossRef

24.

Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M et al (2006) Placenta growth factor in diabetic wound healing. Altered expression and therapeutic potential. Am J Pathol 169:1167–1182. doi:10.2353/ajpath.2006.051314 PubMedCrossRef

25.

Failla CM, Odorisio T, Cianfarani F, Schietroma C, Puddu P, Zambruno G (2000) Placenta growth factor is induced in human keratinocytes during wound healing. J Invest Dermatol 115:388–395. doi:10.1046/j.1523-1747.2000.00085.x PubMedCrossRef

26.

Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF et al (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375–1379. doi:10.1084/jem.176.5.1375 PubMedCrossRef

27.

Oura H, Bertoncini J, Velasco P, Brown LF, Carmeliet P, Detmar M (2003) A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 101:560–567. doi:10.1182/blood-2002-05-1516 PubMedCrossRef

28.

Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B et al (2002) Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone marrow microenvironment. Nat Med 8:841–849PubMed

29.

Carlo-Stella C, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milani R et al (2007) Placental growth factor-1 potentiates hematopoetic progenitor cell mobilization induced by granulocyte coloby-stimulating factor in mice and nonhuman primates. Stem Cells 25:252–261. doi:10.1634/stemcells.2006-0020 PubMedCrossRef

30.

Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA et al (1996) Heterodimers of placenta growth factor/vascular endothelial growth factor. J Biol Chem 271:3154–3162. doi:10.1074/jbc.271.6.3154 PubMedCrossRef

31.

Schomber T, Kopfstein L, Djonov V, Albrecht I, Baeriswyl V, Strittmatter K et al (2007) Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during β cell carcinogenesis. Cancer Res 67:10840–10848. doi:10.1158/0008-5472.CAN-07-1034 PubMedCrossRef

32.

Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D et al (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1:99–108. doi:10.1016/S1535-6108(02)00028-4 PubMedCrossRef

33.

Bjorndahl M, Cao R, Erikksson A, Cao Y (2004) Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ Res 94:1443–1450. doi:10.1161/01.RES.0000129194.61747.bf PubMedCrossRef

34.

Xu L, Cochran DM, Tong RT, Winkler F, Kashiwagi S, Jain RK (2006) Fukumura D (2007) Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homdimers in orthotopic mouse models. Cancer Res 66:3971–3977PubMedCrossRef

35.

Gigante B, Morlino G, Gentile MT, Persico MG, De Falco S (2006) PlGF-/-eNos-/-mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia. FASEB J 20:E70–E79. doi:10.1096/fj.05-4481fje CrossRef

36.

Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T et al (1994) Markedly increased amount of messanger RNAs for vascular endothelial growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54:4233–4237PubMed

37.

Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F et al (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569–1579PubMed

38.

Viglietto G, Romano A, Maglione D, Rambaldi M, Paoletti I, Lago CT et al (1996) Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta growth factor. Oncogene 13:577–587PubMed

39.

Matsumoto K, Suzuki K, Kolke H, Okamura K, Tsuchiya K, Uchida T et al (2003) Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 23:4953–4958PubMed

40.

Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ et al (2004) The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 213:73–82. doi:10.1016/j.canlet.2004.05.020 PubMedCrossRef

41.

Parr C, Watkins G, Boulton M, Cai J, Jiang WG (2005) Placental growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41:2819–2827. doi:10.1016/j.ejca.2005.07.022 PubMedCrossRef

42.

Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH et al (2005) Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54:666–672. doi:10.1136/gut.2004.050831 PubMedCrossRef

43.

Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL et al (2007) Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 250:237–249. doi:10.1016/j.canlet.2006.10.005 PubMedCrossRef

44.

Fisher C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463–475. doi:10.1016/j.cell.2007.08.038 CrossRef

45.

Xu L, Jain RK (2007) Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol Cancer Res 5:873–880. doi:10.1158/1541-7786.MCR-06-0141 PubMedCrossRef

46.

Taylor AP, Goldenberg DM (2007) Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 6:524–531. doi:10.1158/1535-7163.MCT-06-0461 PubMedCrossRef

Titel: The discovery of the placental growth factor and its role in angiogenesis: a historical review
verfasst von: Domenico Ribatti
Publikationsdatum: 01.09.2008
Verlag: Springer Netherlands
Erschienen in: Angiogenesis / Ausgabe 3/2008
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-008-9114-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing

Lysophosphatidic acid (LPA) and angiogenesis

Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent

VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing’s sarcoma vasculature

Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1